Ropinirole for the treatment of early Parkinson disease: A 12-month experience

Archives of Neurology

Volumn 55, Issue 9, 1998, Pages 1211-1216

  Sethi, K D ^a   O'Brien, C F ^b   Hammerstad, J P ^c   Adler, C H ^d   Davis, T L ^e   Taylor, R L ^f   Sanchez Ramos, J ^g   Bertoni, J M ^h   Hauser, R A ⁱ  

^a MEDICAL COLLEGE OF GEORGIA   (United States)

^b Colorado Neurological Institute ^*  (United States)

^c OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^d MAYO CLINIC   (United States)

^e VANDERBILT UNIVERSITY HOSPITAL   (United States)

^f Taylor Medical Group   (United States)

^g VETERANS AFFAIRS MEDICAL CENTER   (United States)

^h CREIGHTON UNIVERSITY MEDICAL CENTER   (United States)

ⁱ UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBIDOPA PLUS LEVODOPA; CHOLINERGIC RECEPTOR BLOCKING AGENT; DOPAMINE 2 RECEPTOR STIMULATING AGENT; LEVODOPA; PLACEBO; ROPINIROLE;

ADULT; AGED; ARTHRALGIA; ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FATIGUE; FEMALE; GASTROINTESTINAL TOXICITY; HUMAN; HYPERKINESIA; INJURY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MYALGIA; NEUROLOGIC DISEASE; PAIN; PARKINSON DISEASE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; AMBULATORY CARE; ANTIPARKINSON AGENTS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INDOLES; MALE; MIDDLE AGED; PARKINSON DISEASE; TREATMENT OUTCOME; UNITED STATES;

EID: 0031721302     PISSN: 00039942     EISSN: None     Source Type: Journal    
DOI: 10.1001/archneur.55.9.1211     Document Type: Article

References (22)

1. Goetz CG. Dopaminergic agonists in the treatment of Parkinson's disease. Neurology. 1990;40(suppl 3):50-54.
2. Piccoli F, Riuggeri RM. Dopaminergic agonists in the treatment of Parkinson's disease: a review. J Neural Transm. 1995;45(suppl):187-195.
3. Rabey JM. Second generation of dopamine agonists: pros and cons. J Neural Transm. 1995;45(suppl):213-224.
4. Montastruc JL, Rascol O, Senard JM. Current status of dopamine agonists in Parkinson's disease management. Drugs. 1993;46:384-393.
5. Kuno S. Dilemma in the treatment of Parkinson's disease with L-dopa. Eur Neurol. 1994;34:17-19.
6. Horstink MWIM, Zijlmans JCM, Pasman JW, et al. Severity of Parkinson's disease is a risk factor for peak-dose dyskinesia. J Neurol Neurosurg Psychiatry. 1990;53:224-226.
7. Blin JB, Bonnet AM, Agid Y. Does levodopa aggravate Parkinson's disease? Neurology. 1988;38:1410-1416.
8. Chase TN, Mouradian NM, Engber TM. Motor response complications and the function of striatal efferent systems. Neurology. 1993;43(suppl 6):S23-S27.
9. Calne DB. Treatment of Parkinson's disease. N Engl J Med. 1993;329: 1021-1027.
10. Nutt JG. Management of parkinsonism and treatment of associated complications. Curr Opin Neurol. 1995;8:327-330.
11. Molho ES, Factor SA, Weiner WJ, et al. The use of pramipexole, a novel dopamine (DA) agonist, in advanced Parkinson's disease. J Neural Transm. 1995;45: 225-230.
12. Pezzoli G, Martignoni E, Pacchetti C, et al. A crossover, controlled study comparing pergolide with bromocriptine as an adjunct to levodopa for the treatment of Parkinson's disease. Neurology. 1995;45(suppl 3):S22-S27.
13. Rinne UK. Early dopamine agonist therapy in Parkinson's disease. Mov Disord. 1989;4(suppl 1):S86-S94.
14. Quinn N. Drug treatment of Parkinson's disease. BMJ. 1995;310:575-579.
15. 2 agonist. Pharmacol Biochem Behav. 1991; 38:147-154.
16. 2 agonist SKF 101468. Lancet. 1989;2:1445-1446.
17. Vidailhet MJ, Bonnet AM, Belal S, Dubois B, Marle C, Agid Y. Ropinirole without levodopa in Parkinson's disease. Lancet. 1990;336:316-317.
18. Brooks DJ, Torjanski N, Burn DJ. Ropinirole in the symptomatic treatment of Parkinson's disease. J Neural Transm. 1995;45(suppl):231-238.
19. Adler CH, Sethi KD, Hauser RA, et al. Ropinirole for the treatment of early Parkinson's disease. Neurology. 1997;49:393-399.
20. Council for International Organization of Medical Sciences. International reporting of adverse drug reactions. In: Final Report of the CIOMS Working Group. Paris, France: Council for International Organization of Medical Sciences; 1991:173-178.
21. Marsden CD, Parkes JD. Success and problems of long-term levodopa therapy in Parkinson's disease. Lancet. 1977;1:345-349.
22. Stacy M, Jankovic J. Current approaches in the treatment of Parkinson's disease. Ann Rev Med. 1993;44:431-440.